Drugmaker Valeant to buy Salix for $10.2B: Sources

Valeant Pharmaceuticals International Inc. has agreed to buy bowel drug maker Salix Pharmaceuticals for roughly $160 per share, according to people directly familiar with the deal. The all-cash deal, which values Salix at about $10.1 billion, could be announced as soon as Sunday, according to these sources, who requested not to be identified.